keyboard_arrow_up

China Cardiovascular Drugs Market Research 2014-2018

Most up-to-date research on "Research on China Cardiovascular Drugs Industry, 2014-2018" to its huge collection of research reports.

Research on China Cardiovascular Drugs Industry, 2014-2018 primarily carries on analyses on cardiovascular drugs market in the following aspects: market scale, the scale of segment markets, current competition status and business performance of major drug manufacturers; meanwhile it makes predictions about prospective market so as to help investors know this industry well and provide decision-making references for them.


With the aged tendency of population in China and the increasing morbidity of chronic diseases which have to be treated with medicines for the rest of patients life, market scale of cardiovascular drugs is expanding. This trend has been reflected in recent years. While in the next few years, with the reform of medical insurance in China and the continuous standardization of pharmaceutical market as well as the unique curative effect of Chinese patent medicines, Chinese patents medicines for cardiovascular diseases will enjoy a promising development prospect.

In 2013 market scale of cardiovascular drugs has reached CNY 17.8 billion in China. At present cardiovascular diseases have a relatively higher morbidity rate among all diseases and also is a kind of disease that is hard to be cured. Along with the changes of peoples life-styles, the difficulties in curing cardiovascular diseases are becoming more prominent. The compound annual growth rate of cardiovascular diseases is 21.6%, and the prevalence rate of cardiovascular diseases will increase further because of the improvements on peoples living standards, the changes of life styles and increasing aging population. The market will be expanded.


On the other hand, patients with cardiovascular diseases have stood at 290 million, and patients with chronic diseases who have received systematic treatment account for a small proportion. In the next ten years, there is a potential for the growth in cardiovascular diseases treatment field. It is predicted that the growth rate will maintain more than 20% from 2014 to 2018. Huidian Research estimates that the sales scale of cardiovascular drugs in China in 2014 will reach about CNY 22 billion, and the figure will be CNY 45 billion by 2018. 

Related Reports
The report firstly introduced Bufferin Film Coated Tablets basic information included Bufferin Film Coated Tablets definition classification application industry chain structure industry overview; international market analysis, China domestic market analysis, Macroeconomic environment and economic situation analysis and influence, Bufferin Film Coated Tablets industry policy and plan,...

Uzbekistan Pharmaceuticals & Healthcare Report We maintain the view that risk-averse pharmaceutical, healthcare and medical device companies should avoid Uzbekistan . While the country has a definite need for pharmaceuticals and medical devices, the regulatory environment remains opaque and state-dominated. Moreover, the government is committed to boosting Uzbekistan's...

About ResearchMoz

ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.

For More Information Kindly Contact: